Jody A. Charnow

Renal function is preserved better compared with radical nephrectomy even when tumors are larger than the traditional 4 cm cutoff.

Added to sunitinib, it prolongs progression-free and overall survival in patients with unfavorable-risk metastatic renal cell carcinoma.

Following guidelines from the AUA and NCCN would miss many cases of disease recurrence following surgery, study suggests.

Larger tumor size, male sex, and higher nephrometry score indicate a greater likelihood that a renal mass is malignant, researchers report.

The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.

Study shows it can provide durable oncologic control with a low risk of tumor recurrence.

Only 17% and 20% of patients undergoing radical or partial nephrectomy, respectively, had a renal mass biopsy in advance of surgery.

The estimated recurrence rate at 10 years was 88.3%, data show.

In a small study, researchers show that ultrasound-guided transhepatic radiofrequency ablation is technically feasible.